As the US Department of Justice opens a criminal probe into the setting of Libor rates, is this the beginning of the end of shady, illiquid and highly profitable trades that banks make between themselves?
Linklaters' Chin-Chong Liew and I-Ping Soong discuss the main legal challenges facing OTC derivatives in Hong Kong and the need for reform amid calls to regulate such instruments in the US and globally.
Japanese firm Taisho Pharmaceutical pays $310 million for six Asia-Pacific brands and the Indonesian business of Bristol-Myers, as it seeks to build its presence in the OTC drug market.